The launch follows a settlement with Teva Women’s Health.
The global marketing research company for the pharmaceutical industry, IMS Health said Watson is the first applicant to submit a complete ANDA and is eligible for 180 days of shared generic market exclusivity.
The data further revealed that LoSEASONIQUE had registered sales of around $28m for the most recent twelve months ending 30 September 2011.
The terms of the deal have not been revealed.